Global Beauty Drinks Market (2020 to 2024) – Featuring Bode Pro, Bottled Science and Kino Biotech Among Others

Press release content from Business Wire. The AP news staff was not involved in its creation.

DUBLIN–(BUSINESS WIRE)–Nov 27, 2020–

The “Global Beauty Drinks Market 2020-2024” report has been added to ResearchAndMarkets.com’s offering.

The beauty drinks market is poised to grow by $161.17 million during 2020-2024 progressing at a CAGR of 3% during the forecast period.

The report on the beauty drinks market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by the growing prevalence of premature aging and growth in online retailing.

The beauty drinks market analysis includes product segment and geographic landscape. This study identifies the increasing frequency of new product launches as one of the prime reasons driving the beauty drinks market growth during the next few years.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.

Companies Mentioned

  • Bode Pro Inc.
  • Bottled Science Ltd.
  • Feed Your Skin JV SL
  • Hangzhou Nutrition Biotechnology Co. Ltd.
  • Kino Biotech Co. Ltd.
  • Lacka Foods Ltd.
  • Sappe Public Co. Ltd.
  • Shiseido Co. Ltd.
  • Skinside (Switzerland) AG
  • Vital Proteins LLC

The beauty drinks market covers the following areas:

  • Beauty drinks market sizing
  • Beauty drinks market forecast
  • Beauty drinks market industry analysis

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. This market research report provides a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Key Topics Covered:

1. Executive Summary

2. Market Landscape

  • Market ecosystem
  • Value chain analysis

3. Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 – 2024

4. Five Forces Analysis

  • Five forces summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

5. Market Segmentation by Product

  • Market segments
  • Comparison by Product
  • Collagen protein – Market size and forecast 2019-2024
  • Vitamins and minerals – Market size and forecast 2019-2024
  • Fruit extracts – Market size and forecast 2019-2024
  • Others – Market size and forecast 2019-2024
  • Market opportunity by Product

6. Market Segmentation by Distribution channel

  • Market segments
  • Comparison by Distribution channel
  • Offline – Market
Read more

Biogen’s Possible Shopping List: 3 Companies the Biotech Might Buy

Biogen (NASDAQ:BIIB) might be in deep trouble. The biotech’s core multiple sclerosis franchise has been hit hard by generic competition this year, and its plan to recoup these lost sales with newer medicines like Vumerity simply isn’t working. What’s more, Biogen and Ionis Pharmaceuticals‘ spinal muscular atrophy medicine, Spinraza, has clearly peaked from a sales standpoint. The drug’s global sales slipped by a hefty 10% in the third quarter, compared to the same period a year ago.

Biogen’s master plan was to wash away these problems by grabbing a surprise approval for its much-maligned Alzheimer’s disease drug candidate aducanumab. After a stinging defeat during last week’s advisory committee meeting, however, the chances of the Food and Drug Administration actually approving this high-value asset appear to be slim to none. 

A researcher counting money at a bench top.

Image source: Getty Images.

Self-inflicted wounds

Worse still, Biogen’s brass didn’t do much to prepare the company for a possible aducanumab rejection. Despite a clear need to bring in a fresh source of revenue or at least a high-value late-stage candidate, the biotech’s braintrust only struck two modest collaboration deals with Denali Therapeutics and Sangamo Therapeutics earlier this year, along with a smallish buyout deal with the gene therapy company Nightstar Therapeutics last year.

The Nightstar deal did bring in the late-stage asset BIIB111 (timrepigene emparvovec) as a possible treatment for a rare, degenerative, X-linked inherited retinal disorder known as choroideremia. But this experimental therapy — if approved — doesn’t have the type of commercial potential to be a true cornerstone product for a large-cap biotech like Biogen.

The biotech’s top line is thus in serious danger of dropping by double digits next year. Therefore, Biogen will likely have to go shopping soon to beef up its near- and long-term outlooks.   

3 possible takeover targets 

Biogen could comfortably spend around $10 billion on business development deals without having to leverage its balance sheet in a significant manner (assuming management nixes its latest $5 billion share repurchase plan). This amount should be more than sufficient to take advantage of this target-rich environment, and get Biogen back on track from a growth standpoint. Here are three intriguing buyout targets the biotech could easily afford and that would dovetail nicely with its core areas of expertise. 

1. Aurinia Pharmaceuticals (NASDAQ:AUPH) is marching toward a January decision date with the FDA for its lupus nephritis drug candidate voclosporin. If approved, voclosporin is expected to generate between $770 million and $1 billion as a treatment for lupus nephritis. Even so, Aurinia’s market cap is only $1.7 billion at present. The market seems to be betting against a fast launch for voclosporin, presumably as a result of Aurinia’s limited commercial infrastructure. 

What’s key to understand is that Biogen has a deep interest in lupus medications, and Aurinia might be able to be had for as little as $3.5 billion to $4 billion. A buyout would also take the risk of a commercial launch off the table for Aurinia shareholders. A merger would thus be a win-win

Read more